Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C31H47O6.Na |
Molecular Weight | 538.691 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[H][C@@]12C[C@@H](O)[C@@]3([H])[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@]4([H])CC[C@]3(C)[C@@]1(C)C[C@H](OC(C)=O)\C2=C(\CCC=C(C)C)C([O-])=O
InChI
InChIKey=HJHVQCXHVMGZNC-JCJNLNMISA-M
InChI=1S/C31H48O6.Na/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32;/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36);/q;+1/p-1/b26-20-;/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/21546624
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21546624
Fusidic acid is a anti-bacterial agent, initially isolated from Fusidium coccineum by Godtfredsen et al (Leo Pharma) in 1960. It is discussed that fusidic acid exerts its anti-microbial effect by inhibiting bacterial elongation factor G, thus suppressing the protein synthesis. Fusidic acid is widely used in Europe under the names Fucidin H(fusidic acid / hydrocortisone acetate), Fucidin (fusidic acid / sodium fusidate) and Fucicort (fusidic acid / betamethasone valerate) for the treatment of primary/secondary skin infections and inflammatory dermatoses.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8475801
Curator's Comment: CNS penetration is low.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Bacterial elongation factor G |
1.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | FUCIDIN Approved UseFor use in the treatment of primary and secondary skin infections caused by sensitive strains of Staphylococcus aureus, Streptococcusspp and Corynebacterium minutissimum. Primary skin infections that may be expected to respond to treatment with FUCIDIN OINTMENT (sodium fusidate) and CREAM (fusidic acid) include: impetigo contagiosa, erythrasma and secondary skin infections such as infected wounds and infected burns. |
|||
Curative | FUCICORT Approved UseFUCICORT is indicated in inflammatory dermatoses where bacterial infection is present or likely to occur. Inflammatory dermatoses include atopic eczema, discoid eczema, seborrheic dermatitis, contact dermatitis, lichen simplex chronicus, psoriasis, discoid lupus erythematosus |
PubMed
Title | Date | PubMed |
---|---|---|
Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains. | 1973 Sep |
|
Susceptibility of mycobacteria to fusidic acid. | 1990 Apr |
|
Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages. | 1994 May-Jun |
|
Acute renal failure in association with fusidic acid. | 1997 Jun |
|
Antimycobacterial plant terpenoids. | 2001 Nov |
|
Sideroblastic anaemia during fusidic acid treatment. | 2004 May |
|
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014 Jan |
Patents
Sample Use Guides
A small amount of fucidin ointment(sodium fusidate) or cream (fusidic acid) should be
applied to the lesion 3 or 4 times daily until favourable results are achieved. Futicort cream (fusidic acid / betamethasone valerate) is applied 2 times daily.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21546624
In vitro fusidic acid inhibited S. aureus (minimum inhibitory concentration [MIC], 0.25 ug/mL), Micrococcus luteus (MIC, 0.25–0.5 ug/mL), Corynebacterium spp. (MIC, 0.06–0.12 ug/mL), Moraxella catarrhalis (MIC, 0.06–0.12 ug/mL), and Neisseria meningitidis (MIC, 0.12–0.25 ug/mL).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28394
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
||
|
FDA ORPHAN DRUG |
723519
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
||
|
FDA ORPHAN DRUG |
400513
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
||
|
NCI_THESAURUS |
C52588
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
23672955
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
SUB12288MIG
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
100000079317
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
212-030-3
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
m5616
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
J7P3696BCQ
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
DTXSID9045552
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
J7P3696BCQ
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
9874
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | RxNorm | ||
|
751-94-0
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL383466
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
DBSALT000340
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY | |||
|
C65792
Created by
admin on Fri Dec 15 15:01:08 GMT 2023 , Edited by admin on Fri Dec 15 15:01:08 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD